University of Kansas Hospital - Indian Creek Campus

Clinical research site in Overland Park, Kansas · 10710 NALL AVE, OVERLAND PARK, KS 66211-1206 · (913) 588-2361

Part of University of Kansas Medical Center

As of July 2026, 33 paid clinical trials are recruiting at University of Kansas Hospital - Indian Creek Campus in Overland Park, Kansas. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Stage IV Lung Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at University of Kansas Hospital - Indian Creek Campus (33)

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1105 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting·Listed May 2023

Apply to this trial

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for Locally Advanced Cervical Adenocarcinoma

289 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07061977·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

776 locations incl. Fairhope

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for Anatomic Stage I Breast Cancer AJCC v8

585 locations incl. Phoenix

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06876714·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

for Adenocarcinoma of the Colon

365 locations incl. Fairbanks

Sponsor: NRG Oncology

Sex: All·Age: 45 - 70

Code: NCT05080673·Recruiting·Listed Oct 2021

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

525 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting·Listed Sep 2023

Apply to this trial

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

for Previously Treated Non-Small Cell Lung Cancer

950 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03851445·Phase 2, Phase 3·Recruiting·Listed Feb 2019

Apply to this trial

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for Pancreatic Acinar Cell Carcinoma

261 locations incl. Kingman

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04858334·Phase 2·Recruiting·Listed Apr 2021

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

328 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

for Malignant Solid Neoplasm

365 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT06295367·Recruiting·Listed Mar 2024

Apply to this trial

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

372 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642572·Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

223 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06317649·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

for Non-Muscle Invasive Bladder Urothelial Carcinoma

127 locations incl. Fayetteville

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06770582·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

for Metastatic Salivary Gland Carcinoma

142 locations incl. Dublin

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05408845·Phase 2·Recruiting·Listed Jun 2022

Apply to this trial

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

209 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554406·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

for Metastatic Head and Neck Squamous Cell Carcinoma

170 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06589804·Phase 3·Recruiting·Listed Sep 2024

Apply to this trial

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

164 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554393·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

for Stage I Breast Cancer

707 locations incl. Mobile

Sponsor: NRG Oncology

Sex: All·Age: 50 - 70

Code: NCT04852887·Phase 3·Recruiting·Listed Apr 2021

Apply to this trial

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

381 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06616584·Phase 2, Phase 3·Recruiting·Listed Sep 2024

Apply to this trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

241 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18 Minutes+

Code: NCT06031688·Phase 2·Recruiting·Listed Sep 2023

Apply to this trial

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

for Castration-Resistant Prostate Carcinoma

102 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06632977·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

for Lung Non-Small Cell Carcinoma

243 locations incl. Jonesboro

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06116682·Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

for Advanced Malignant Solid Neoplasm

23 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05327010·Phase 2·Recruiting·Listed Apr 2022

Apply to this trial

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

for Advanced Malignant Solid Neoplasm

15 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05691491·Phase 1, Phase 2·Recruiting·Listed Jan 2023

Apply to this trial

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

for Extensive Stage Lung Small Cell Carcinoma

38 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06287775·Phase 1, Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

for Breast Carcinoma

464 locations incl. Fairbanks

Sponsor: Wake Forest University Health Sciences

Sex: All·Age: 18+

Code: NCT06418204·Recruiting·Listed May 2024

Apply to this trial

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

for Acute Myeloid Leukemia

19 locations incl. Orange

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 75

Code: NCT05886049·Phase 1·Recruiting·Listed Jun 2023

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

473 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting·Listed Jan 2020

Apply to this trial

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

for Autoimmune Disease

41 locations incl. Sacramento

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03816345·Phase 1·Recruiting·Listed Jan 2019

Apply to this trial

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

for Malignant Solid Neoplasm

33 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642611·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

for Metastatic Colorectal Adenocarcinoma

13 locations incl. Gainesville

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06696768·Phase 1·Recruiting·Listed Nov 2024

Apply to this trial

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

for Cardiotoxicity

144 locations incl. Duarte

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03418961·Phase 3·Recruiting·Listed Feb 2018

Apply to this trial

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

for Cutaneous Melanoma, Stage II

130 locations incl. Mobile

Sponsor: Melanoma and Skin Cancer Trials Limited

Sex: All·Age: 18+

Code: NCT03860883·Recruiting·Listed Mar 2019

Apply to this trial

More research sites in Overland Park

University of Kansas Cancer Center-Overland Park (52 trials)
University of Kansas Hospital-Indian Creek Campus (32 trials)
Kansas City Heart Rhythm Institute (10 trials)
Overland Park Regional Medical Center (10 trials)
Kansas City Heart Rhythm Institute - Roe Clinic (6 trials)
Menorah Medical Center (6 trials)
Midwest Heart and Vascular Specialists (5 trials)
Dr. Vince Clinical Research (4 trials)
Clinical Associates Midwest, LLC (4 trials)
Collective Medical Research (3 trials)

Explore more

Paid clinical trials in Overland Park, KS · Kansas clinical trials